PT - JOURNAL ARTICLE AU - Garcia-Beltran, Wilfredo F. AU - Lam, Evan C. AU - Denis, Kerri St. AU - Nitido, Adam D. AU - Garcia, Zeidy H. AU - Hauser, Blake M. AU - Feldman, Jared AU - Pavlovic, Maia N. AU - Gregory, David J. AU - Poznansky, Mark C. AU - Sigal, Alex AU - Schmidt, Aaron G. AU - Iafrate, A. John AU - Naranbhai, Vivek AU - Balazs, Alejandro B. TI - Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity AID - 10.1101/2021.02.14.21251704 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.14.21251704 4099 - http://medrxiv.org/content/early/2021/03/12/2021.02.14.21251704.short 4100 - http://medrxiv.org/content/early/2021/03/12/2021.02.14.21251704.full AB - Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However, ongoing surveillance has revealed the emergence of variants harboring mutations in spike, the main target of neutralizing antibodies. To understand the impact of these variants, we evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2. Five of the 10 pseudoviruses, harboring receptor-binding domain mutations, including K417N/T, E484K, and N501Y, were highly resistant to neutralization. Cross-neutralization of B.1.351 variants was comparable to SARS-CoV and bat-derived WIV1-CoV, suggesting that a relatively small number of mutations can mediate potent escape from vaccine responses. While the clinical impact of neutralization resistance remains uncertain, these results highlight the potential for variants to escape from neutralizing humoral immunity and emphasize the need to develop broadly protective interventions against the evolving pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementB.M.H. is supported by award Number T32GM007753 from the National Institute of General Medical Sciences. J.F. is supported by T32AI007245. D.J.G., M.C.P., and M.N.P. were supported by the VIC Innovation fund. A.S was supported by the Bill and Melinda Gates Investment INV-018944 (AS) and by the South African Medical Research Council and the Department of Science and Innovation (TdO), A.G.S. was supported by NIH R01 AI146779 and a Massachusetts Consortium on Pathogenesis Readiness (MassCPR) grant. A.J.I. is supported by the Lambertus Family Foundation. A.B.B. was supported by the National Institutes for Drug Abuse (NIDA) Avenir New Innovator Award DP2DA040254, the MGH Transformative Scholars Program as well as funding from the Charles H. Hood Foundation. This independent research was supported by the Gilead Sciences Research Scholars Program in HIV.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Use of human samples was approved by Partners Institutional Review Board (protocol 2020P002274)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study assessed the neutralization potency of sera obtained from vaccinated individuals and was not a clinical trial. De-identified raw data of the results of serological assays can be provided upon request.